NEW YORK (GenomeWeb News) – The DNA Repair Company has licensed the exclusive North American rights to a test from Helsinki University Central Hospital that predicts how women with breast cancer will respond to a common chemotherapy drug.
 
The Boston-based company acquired the rights to the test through an agreement with Licentia, a Finnish technology transfer company. DNAR plans to use a variant of the NQO1 enzyme to create personalized medicine tests.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.